×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Ideaya Biosciences Inc. (IDYA) NASDAQ

$43.88 0.57 (1.32%)

Market Cap: $3.27B

As of 03/28/24 04:00 PM EDT. Market closed.

(IDYA)

Ideaya Biosciences Inc. (IDYA)
NASDAQ

$43.88
0.57 (1.32%)

Market Cap: $3.27B

As of 03/28/24 04:00 PM EDT. Market closed.

Add to Portfolio

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ... read more

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california. read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
URL
Address
7000 Shoreline Ct Ste 350, California, South San Francisco, 94080-7604.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
CEO
Yujiro Hata
Address
7000 Shoreline Ct Ste 350, California, South San Francisco, 94080-7604.
PRICE CHART FOR IDEAYA BIOSCIENCES INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$43.90
Previous Close
$43.31
Days Range
$42.54 - $43.53
52 week range
$13.29 - $47.74
Volume
729,125
Avg. Volume (30 days)
770,448
Market Cap
$3.27B
Dividend Yield
-
P/E
(28.96)
Shares Outstanding
74,560,273
Open
$43.90
Previous Close
$43.31
Days Range
$42.54 - $43.53
52 week range
$13.29 - $47.74
Volume
729,125
Avg. Volume (30 days)
770,448
Market Cap
$3.27B
Dividend Yield
-
P/E
(28.96)
Shares Outstanding
74,560,273
FINANCIAL STATEMENTS FOR IDEAYA BIOSCIENCES INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR IDEAYA BIOSCIENCES INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Ruiz Briseno AndresSee RemarksFeb 09, 2024 Sale$46.022,00092,04524,531Feb 13, 2024, 04:59 PM
Hata Yujiro SPresident and CEOFeb 08, 2024 Option Exercise$4.3175,815326,763753,702Feb 12, 2024, 04:27 PM
Hata Yujiro SPresident and CEOFeb 09, 2024 Option Exercise$4.3123,557101,531701,444Feb 12, 2024, 04:27 PM
Hata Yujiro SPresident and CEOFeb 09, 2024 Sale$45.5423,5571,072,715677,887Feb 12, 2024, 04:27 PM
Hata Yujiro SPresident and CEOFeb 08, 2024 Sale$45.1575,8153,422,835677,887Feb 12, 2024, 04:27 PM
Hata Yujiro SPresident and CEOFeb 01, 2024 Option Exercise$4.316282,707678,515Feb 05, 2024, 06:05 PM
Hata Yujiro SPresident and CEOFeb 01, 2024 Sale$45.0062828,260677,891Feb 05, 2024, 06:05 PM
Ruiz Briseno AndresSee RemarksJan 22, 2024 Sale$42.032,00084,05026,531Jan 24, 2024, 07:12 PM
Ruiz Briseno AndresSee RemarksJan 12, 2024 Sale$38.012,00076,02628,531Jan 17, 2024, 05:41 PM
Hata Yujiro SPresident and CEOJan 12, 2024 Option Exercise$4.3112,26152,845690,148Jan 17, 2024, 05:40 PM
Hata Yujiro SPresident and CEOJan 16, 2024 Option Exercise$4.3162,739270,405740,626Jan 17, 2024, 05:40 PM
Hata Yujiro SPresident and CEOJan 12, 2024 Sale$40.0412,261490,913677,887Jan 17, 2024, 05:40 PM
Hata Yujiro SPresident and CEOJan 16, 2024 Sale$40.1762,7392,519,968677,887Jan 17, 2024, 05:40 PM
Throne JasonChief Legal OfficerDec 18, 2023 Option Exercise$7.0110,00070,10010,000Dec 19, 2023, 05:37 PM
Throne JasonChief Legal OfficerDec 15, 2023 Option Exercise$13.3410,000133,40010,000Dec 19, 2023, 05:37 PM
Throne JasonChief Legal OfficerDec 15, 2023 Sale$35.0410,000350,3710Dec 19, 2023, 05:37 PM
Hata Yujiro SPresident and CEODec 15, 2023 Option Exercise$4.3175,000323,250752,887Dec 19, 2023, 05:34 PM
Hata Yujiro SPresident and CEODec 15, 2023 Sale$35.0375,0002,627,618677,887Dec 19, 2023, 05:34 PM
Ruiz Briseno AndresSee RemarksDec 14, 2023 Sale$34.002,00068,00230,859Dec 18, 2023, 05:45 PM
Throne JasonChief Legal OfficerNov 03, 2023 Option Exercise$12.865,16366,3965,163Nov 07, 2023, 05:47 PM
Throne JasonChief Legal OfficerNov 03, 2023 Sale$30.095,163155,3600Nov 07, 2023, 05:47 PM
Throne JasonChief Legal OfficerSep 12, 2023 Option Exercise$12.861,00012,8601,000Sep 14, 2023, 05:23 PM
Throne JasonChief Legal OfficerSep 12, 2023 Sale$30.011,00030,005500Sep 14, 2023, 05:23 PM
Throne JasonChief Legal OfficerSep 05, 2023 Option Exercise$12.861,73722,3381,737Sep 06, 2023, 06:37 PM
Throne JasonChief Legal OfficerSep 01, 2023 Option Exercise$12.862,10027,0062,100Sep 06, 2023, 06:37 PM
Throne JasonChief Legal OfficerSep 05, 2023 Sale$30.031,73752,1600Sep 06, 2023, 06:37 PM
Throne JasonChief Legal OfficerSep 01, 2023 Sale$30.032,10063,0630Sep 06, 2023, 06:37 PM
Ruiz Briseno AndresSee RemarksSep 01, 2023 Sale$30.012,00060,01632,531Sep 06, 2023, 06:36 PM
Stone Paul A.Chief Financial OfficerAug 29, 2023 Sale$28.875,000144,3529,303Aug 31, 2023, 05:49 PM
Stone Paul A.Chief Financial OfficerAug 21, 2023 Sale$26.4097825,81914,303Aug 23, 2023, 06:31 PM
Stone Paul A.Chief Financial OfficerAug 18, 2023 Sale$26.383,822100,82015,281Aug 18, 2023, 06:33 PM
Stone Paul A.Chief Financial OfficerAug 16, 2023 Sale$26.432005,28519,203Aug 18, 2023, 06:33 PM
Throne JasonChief Legal OfficerAug 09, 2023 Option Exercise$13.345,00066,7005,000Aug 11, 2023, 07:22 PM
Throne JasonChief Legal OfficerAug 09, 2023 Sale$25.095,000125,4290Aug 11, 2023, 07:22 PM
Stone Paul A.Chief Financial OfficerAug 09, 2023 Sale$25.052,50062,61319,303Aug 11, 2023, 07:21 PM
Throne JasonChief Legal OfficerJul 10, 2023 Option Exercise$10.099,48595,7409,485Jul 12, 2023, 05:25 PM
Throne JasonChief Legal OfficerJul 10, 2023 Sale$23.009,485218,1780Jul 12, 2023, 05:25 PM
Throne JasonChief Legal OfficerJun 01, 2023 Option Exercise$7.013,55324,9073,553Jun 02, 2023, 05:29 PM
Throne JasonChief Legal OfficerMay 31, 2023 Option Exercise$7.014323,028432Jun 02, 2023, 05:29 PM
Throne JasonChief Legal OfficerJun 01, 2023 Sale$23.023,55381,7920Jun 02, 2023, 05:29 PM
Throne JasonChief Legal OfficerMay 31, 2023 Sale$23.004329,9380Jun 02, 2023, 05:29 PM
Throne JasonChief Legal OfficerMay 22, 2023 Option Exercise$7.015003,505500May 24, 2023, 05:51 PM
Throne JasonChief Legal OfficerMay 22, 2023 Sale$23.0050011,5000May 24, 2023, 05:51 PM
Stone Paul A.Chief Financial OfficerApr 13, 2023 Option Exercise$4.628,00036,96021,803Apr 14, 2023, 01:20 PM
Hata Yujiro SPresident and CEOApr 12, 2023 Option Exercise$4.3111,60150,000677,887Apr 13, 2023, 04:11 PM
Stone Paul A.SVP, Chief Financial OfficerMay 28, 2021 Option Exercise$11.368599,76213,803Apr 14, 2022, 04:10 PM
Dillon Michael P.SVP, Chief Scientific OfficerOct 04, 2021 Option Exercise$11.081,50016,62080,289Oct 07, 2021, 04:11 PM
Dillon Michael P.SVP, Chief Scientific OfficerOct 04, 2021 Sale$26.361,50039,54579,789Oct 07, 2021, 04:11 PM
Dillon Michael P.SVP, Chief Scientific OfficerSep 08, 2021 Option Exercise$6.8711,38478,26490,173Sep 09, 2021, 07:24 PM
Dillon Michael P.SVP, Chief Scientific OfficerSep 07, 2021 Option Exercise$4.3111650078,905Sep 09, 2021, 07:24 PM
Dillon Michael P.SVP, Chief Scientific OfficerSep 08, 2021 Sale$27.4211,384312,09378,989Sep 09, 2021, 07:24 PM
Dillon Michael P.SVP, Chief Scientific OfficerSep 07, 2021 Sale$27.461163,18578,789Sep 09, 2021, 07:24 PM
Stone Paul A.SVP, Chief Financial OfficerSep 07, 2021 Sale$27.422,50068,54212,944Sep 09, 2021, 05:41 PM
Dillon Michael P.SVP, Chief Scientific OfficerSep 02, 2021 Sale$25.0910,000250,94378,789Sep 07, 2021, 06:48 PM
Dillon Michael P.SVP, Chief Scientific OfficerAug 09, 2021 Option Exercise$4.311,5006,465100,289Aug 11, 2021, 05:19 PM
Dillon Michael P.SVP, Chief Scientific OfficerAug 09, 2021 Sale$22.9811,500264,26989,189Aug 11, 2021, 05:19 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 27, 2021 Option Exercise$5.6210,00056,150108,789Jul 29, 2021, 05:18 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 27, 2021 Sale$25.1510,000251,46098,789Jul 29, 2021, 05:18 PM
Throne JasonSVP, General CounselJul 27, 2021 Option Exercise$13.3410,000133,40010,000Jul 29, 2021, 05:17 PM
Throne JasonSVP, General CounselJul 27, 2021 Sale$25.1710,000251,6830Jul 29, 2021, 05:17 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 06, 2021 Option Exercise$6.921,50010,380100,289Jul 08, 2021, 07:01 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 06, 2021 Sale$22.241,50033,35898,889Jul 08, 2021, 07:01 PM
Throne JasonSVP, General CounselJul 06, 2021 Option Exercise$8.5210,00085,22910,000Jul 08, 2021, 07:00 PM
Throne JasonSVP, General CounselJul 06, 2021 Sale$22.2410,000222,4083,532Jul 08, 2021, 07:00 PM
Dillon Michael P.SVP, Chief Scientific OfficerFeb 09, 2021 Option Exercise$6.925,00034,600103,789Feb 10, 2021, 07:31 PM
Dillon Michael P.SVP, Chief Scientific OfficerFeb 09, 2021 Sale$20.745,000103,69698,789Feb 10, 2021, 07:31 PM
Lackner MarkSVP, Head of BiologyFeb 10, 2021 Option Exercise$6.985964,160596Feb 10, 2021, 06:53 PM
Lackner MarkSVP, Head of BiologyFeb 09, 2021 Option Exercise$6.981,1047,7061,104Feb 10, 2021, 06:53 PM
Lackner MarkSVP, Head of BiologyFeb 08, 2021 Option Exercise$6.983002,094300Feb 10, 2021, 06:53 PM
Lackner MarkSVP, Head of BiologyFeb 10, 2021 Sale$21.0059612,5160Feb 10, 2021, 06:53 PM
Lackner MarkSVP, Head of BiologyFeb 09, 2021 Sale$21.051,10423,2340Feb 10, 2021, 06:53 PM
Lackner MarkSVP, Head of BiologyFeb 08, 2021 Sale$21.013006,302200Feb 10, 2021, 06:53 PM
BVF PARTNERS L P/ILSee Explanation of ResponsesFeb 02, 2021 Sale$18.0046,409835,3621,642,186Feb 04, 2021, 05:15 PM
Lackner MarkSVP, Head of BiologyJan 26, 2021 Option Exercise$6.391,5009,5802,501Jan 28, 2021, 04:59 PM
Lackner MarkSVP, Head of BiologyJan 26, 2021 Sale$18.462,50146,158800Jan 28, 2021, 04:59 PM
Hata Yujiro SPresident and CEODec 22, 2020 Option Exercise$4.318,00034,480666,286Dec 23, 2020, 04:06 PM
Dillon Michael P.SVP, Chief Scientific OfficerDec 18, 2020 Option Exercise$4.317,75033,40298,789Dec 22, 2020, 05:35 PM
Throne JasonSVP, General CounselDec 04, 2020 Sale$15.371,97930,4101,579Dec 08, 2020, 04:03 PM
5AM Ventures IV, L.P.10% OwnerNov 11, 2020 Sale$13.66800,00010,928,0002,187,428Nov 13, 2020, 08:53 PM
BVF PARTNERS L P/IL10% OwnerJun 30, 2020 Buy$13.322,53133,7041,667,420Jul 02, 2020, 06:51 PM
BVF PARTNERS L P/IL10% OwnerJun 22, 2020 Buy$13.9319,732274,9601,665,899Jun 22, 2020, 07:52 PM
BVF PARTNERS L P/IL10% OwnerJun 19, 2020 Buy$14.3998,2641,413,9701,655,375Jun 22, 2020, 07:52 PM
Stone Paul A.Chief Financial OfficerJun 17, 2020 Option Exercise$4.623,10014,32218,100Jun 19, 2020, 07:46 PM
Stone Paul A.Chief Financial OfficerJun 17, 2020 Sale$17.973,10055,71715,600Jun 19, 2020, 07:46 PM
Lackner MarkSVP, Head of BiologyJun 17, 2020 Option Exercise$4.623731,723373Jun 18, 2020, 06:03 PM
Lackner MarkSVP, Head of BiologyJun 16, 2020 Option Exercise$5.626,75037,9426,750Jun 18, 2020, 06:03 PM
Lackner MarkSVP, Head of BiologyJun 16, 2020 Sale$14.936,750100,7610Jun 18, 2020, 06:03 PM
Lackner MarkSVP, Head of BiologyJun 17, 2020 Sale$19.913737,4280Jun 18, 2020, 06:03 PM
Throne JasonVP, General CounselJun 04, 2020 Sale$8.662,20519,0870Jun 08, 2020, 04:51 PM
Lackner MarkSVP, Head of BiologyJun 02, 2020 Sale$9.218457,779437Jun 04, 2020, 05:40 PM
Hata Yujiro SPresident and CEOApr 15, 2020 Option Exercise$4.3147,564205,001658,286Apr 16, 2020, 05:33 PM
Stone Paul A.Chief Financial OfficerMar 30, 2020 Option Exercise$4.625,00023,10015,000Apr 01, 2020, 04:06 PM
Hata Yujiro SPresident and CEOJul 30, 2019 Option Exercise$4.3115,00064,650610,722Aug 01, 2019, 12:20 PM
Hager JeffreySVP, Chief Technology OfficerJul 26, 2019 Option Exercise$4.315,19722,399127,853Jul 30, 2019, 07:20 PM
Stone Paul A.SVP, General CounselJul 26, 2019 Option Exercise$4.6210,00046,20010,000Jul 29, 2019, 04:27 PM
Hager JeffreySVP, Chief Technology OfficerJul 10, 2019 Option Exercise$4.317,14530,795122,656Jul 26, 2019, 12:50 PM
Hager JeffreySVP, Chief Technology OfficerJun 19, 2019 Option Exercise$4.318,62837,187115,511Jul 26, 2019, 12:50 PM
Alexandria Venture Investments, LLC10% OwnerMay 28, 2019 Buy$10.0050,000500,000432,384May 30, 2019, 06:12 PM
DIEKMAN JOHN DDirectorMay 28, 2019 Buy$10.00250,0002,500,0002,844,545May 28, 2019, 09:14 PM
Stone Paul A.SVP, General CounselMay 28, 2019 Buy$10.00250,0002,500,0002,844,545May 28, 2019, 09:08 PM
5AM Ventures IV, L.P.10% OwnerMay 28, 2019 Buy$10.00750,0007,500,0002,844,545May 28, 2019, 08:40 PM
SHANNON TIMOTHY MDirectorMay 28, 2019 Buy$10.00400,0004,000,0002,660,713May 28, 2019, 04:56 PM
CANAAN X L.P.10% OwnerMay 28, 2019 Buy$10.00400,0004,000,0002,660,713May 28, 2019, 04:55 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Ruiz Briseno AndresSee Remarks02/09/202492,045
Hata Yujiro SPresident and CEO02/08/2024326,763
Hata Yujiro SPresident and CEO02/09/2024101,531
Hata Yujiro SPresident and CEO02/09/20241,072,715
Hata Yujiro SPresident and CEO02/08/20243,422,835
Hata Yujiro SPresident and CEO02/01/20242,707
Hata Yujiro SPresident and CEO02/01/202428,260
Ruiz Briseno AndresSee Remarks01/22/202484,050
Ruiz Briseno AndresSee Remarks01/12/202476,026
Hata Yujiro SPresident and CEO01/12/202452,845
Hata Yujiro SPresident and CEO01/16/2024270,405
Hata Yujiro SPresident and CEO01/12/2024490,913
Hata Yujiro SPresident and CEO01/16/20242,519,968
Throne JasonChief Legal Officer12/18/202370,100
Throne JasonChief Legal Officer12/15/2023133,400
Throne JasonChief Legal Officer12/15/2023350,371
Hata Yujiro SPresident and CEO12/15/2023323,250
Hata Yujiro SPresident and CEO12/15/20232,627,618
Ruiz Briseno AndresSee Remarks12/14/202368,002
Throne JasonChief Legal Officer11/03/202366,396
Throne JasonChief Legal Officer11/03/2023155,360
Throne JasonChief Legal Officer09/12/202312,860
Throne JasonChief Legal Officer09/12/202330,005
Throne JasonChief Legal Officer09/05/202322,338
Throne JasonChief Legal Officer09/01/202327,006
Throne JasonChief Legal Officer09/05/202352,160
Throne JasonChief Legal Officer09/01/202363,063
Ruiz Briseno AndresSee Remarks09/01/202360,016
Stone Paul A.Chief Financial Officer08/29/2023144,352
Stone Paul A.Chief Financial Officer08/21/202325,819
Stone Paul A.Chief Financial Officer08/18/2023100,820
Stone Paul A.Chief Financial Officer08/16/20235,285
Throne JasonChief Legal Officer08/09/202366,700
Throne JasonChief Legal Officer08/09/2023125,429
Stone Paul A.Chief Financial Officer08/09/202362,613
Throne JasonChief Legal Officer07/10/202395,740
Throne JasonChief Legal Officer07/10/2023218,178
Throne JasonChief Legal Officer06/01/202324,907
Throne JasonChief Legal Officer05/31/20233,028
Throne JasonChief Legal Officer06/01/202381,792
Throne JasonChief Legal Officer05/31/20239,938
Throne JasonChief Legal Officer05/22/20233,505
Throne JasonChief Legal Officer05/22/202311,500
Stone Paul A.Chief Financial Officer04/13/202336,960
Hata Yujiro SPresident and CEO04/12/202350,000
Stone Paul A.SVP, Chief Financial Officer05/28/20219,762
Dillon Michael P.SVP, Chief Scientific Officer10/04/202116,620
Dillon Michael P.SVP, Chief Scientific Officer10/04/202139,545
Dillon Michael P.SVP, Chief Scientific Officer09/08/202178,264
Dillon Michael P.SVP, Chief Scientific Officer09/07/2021500
Dillon Michael P.SVP, Chief Scientific Officer09/08/2021312,093
Dillon Michael P.SVP, Chief Scientific Officer09/07/20213,185
Stone Paul A.SVP, Chief Financial Officer09/07/202168,542
Dillon Michael P.SVP, Chief Scientific Officer09/02/2021250,943
Dillon Michael P.SVP, Chief Scientific Officer08/09/20216,465
Dillon Michael P.SVP, Chief Scientific Officer08/09/2021264,269
Dillon Michael P.SVP, Chief Scientific Officer07/27/202156,150
Dillon Michael P.SVP, Chief Scientific Officer07/27/2021251,460
Throne JasonSVP, General Counsel07/27/2021133,400
Throne JasonSVP, General Counsel07/27/2021251,683
Dillon Michael P.SVP, Chief Scientific Officer07/06/202110,380
Dillon Michael P.SVP, Chief Scientific Officer07/06/202133,358
Throne JasonSVP, General Counsel07/06/202185,229
Throne JasonSVP, General Counsel07/06/2021222,408
Dillon Michael P.SVP, Chief Scientific Officer02/09/202134,600
Dillon Michael P.SVP, Chief Scientific Officer02/09/2021103,696
Lackner MarkSVP, Head of Biology02/10/20214,160
Lackner MarkSVP, Head of Biology02/09/20217,706
Lackner MarkSVP, Head of Biology02/08/20212,094
Lackner MarkSVP, Head of Biology02/10/202112,516
Lackner MarkSVP, Head of Biology02/09/202123,234
Lackner MarkSVP, Head of Biology02/08/20216,302
BVF PARTNERS L P/ILSee Explanation of Responses02/02/2021835,362
Lackner MarkSVP, Head of Biology01/26/20219,580
Lackner MarkSVP, Head of Biology01/26/202146,158
Hata Yujiro SPresident and CEO12/22/202034,480
Dillon Michael P.SVP, Chief Scientific Officer12/18/202033,402
Throne JasonSVP, General Counsel12/04/202030,410
5AM Ventures IV, L.P.10% Owner11/11/202010,928,000
BVF PARTNERS L P/IL10% Owner06/30/202033,704
BVF PARTNERS L P/IL10% Owner06/22/2020274,960
BVF PARTNERS L P/IL10% Owner06/19/20201,413,970
Stone Paul A.Chief Financial Officer06/17/202014,322
Stone Paul A.Chief Financial Officer06/17/202055,717
Lackner MarkSVP, Head of Biology06/17/20201,723
Lackner MarkSVP, Head of Biology06/16/202037,942
Lackner MarkSVP, Head of Biology06/16/2020100,761
Lackner MarkSVP, Head of Biology06/17/20207,428
Throne JasonVP, General Counsel06/04/202019,087
Lackner MarkSVP, Head of Biology06/02/20207,779
Hata Yujiro SPresident and CEO04/15/2020205,001
Stone Paul A.Chief Financial Officer03/30/202023,100
Hata Yujiro SPresident and CEO07/30/201964,650
Hager JeffreySVP, Chief Technology Officer07/26/201922,399
Stone Paul A.SVP, General Counsel07/26/201946,200
Hager JeffreySVP, Chief Technology Officer07/10/201930,795
Hager JeffreySVP, Chief Technology Officer06/19/201937,187
Alexandria Venture Investments, LLC10% Owner05/28/2019500,000
DIEKMAN JOHN DDirector05/28/20192,500,000
Stone Paul A.SVP, General Counsel05/28/20192,500,000
5AM Ventures IV, L.P.10% Owner05/28/20197,500,000
SHANNON TIMOTHY MDirector05/28/20194,000,000
CANAAN X L.P.10% Owner05/28/20194,000,000
Load More Insider Transactions
FUNDS WITH A POSITION IN IDEAYA BIOSCIENCES INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.5,436,6680.00493%18.35%Other
ADAGE CAPITAL PARTNERS GP, L.L.C.2,925,0940.22%27.9%Other
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)2,630,2921.73%15.94%Other
CAPITAL RESEARCH GLOBAL INVESTORS1,976,8700.02%43.58%Growth At A Reasonable Price
HOLOCENE ADVISORS, LP1,700,1350.24%64.59%Growth At A Reasonable Price
GEODE CAPITAL MANAGEMENT, LLC1,351,3370.00503%16.38%Other
BAKER BROS. ADVISORS LP1,062,1230.43%No changeOther
DRIEHAUS CAPITAL MANAGEMENT LLC912,7860.39%30.87%Growth
PLATINUM INVESTMENT MANAGEMENT LTD662,3430.96%-13.61%Growth At A Reasonable Price, Value
FISHER ASSET MANAGEMENT, LLC539,6760.01%1611.9%Other
D. E. SHAW & CO., INC.529,5060.02%21.35%Other
BALYASNY ASSET MANAGEMENT L.P.466,2710.03%NewEvent Driven
CANDRIAM S.C.A.395,0190.1%-8.14%Other
UBS OCONNOR LLC74,5750.19%-40.88%Value
ALPS ADVISORS INC42,4500.01%-0.07%Other
TUDOR INVESTMENT CORP ET AL20,9310.00566%ExitedEvent Driven, Other
AQR CAPITAL MANAGEMENT LLC15,8790.00106%-7.05%Other
CHANGE IN SHARES OUTSTANDING FOR IDEAYA BIOSCIENCES INC
STOCK BUYBACKS FOR IDEAYA BIOSCIENCES INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
8.89%
1Q
12/31/2023
06/30/2023
16.14%
2Q
12/31/2023
03/31/2023
35.07%
3Q
12/31/2023
12/31/2022
35.53%
4Q
12/31/2023
09/30/2022
58.92%
5Q
12/31/2023
06/30/2022
68.99%
6Q
12/31/2023
03/31/2022
69.29%
7Q
12/31/2023
12/31/2021
69.53%
8Q
12/31/2023
09/30/2021
72.97%
9Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
8.89%
1Q
06/30/2023
16.14%
2Q
03/31/2023
35.07%
3Q
12/31/2022
35.53%
4Q
09/30/2022
58.92%
5Q
06/30/2022
68.99%
6Q
03/31/2022
69.29%
7Q
12/31/2021
69.53%
8Q
09/30/2021
72.97%
9Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR IDEAYA BIOSCIENCES INC
LOADING...